A Phase 4 interventional study of Carboplatin and Cyclophosphamide in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 6 sites in India. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-12.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 145 studies testing carboplatin in Breast Neoplasms — 17 open to participants now, 34 under way, 9 of them phase 3. Carboplatin · Breast Neoplasms.
Among the 145 studies testing carboplatin in Breast Neoplasms, this one is the 46th largest by enrollment of the 142 interventional ones that give a count, is one of 11 that started in 2015, is one of 5 in phase 4, and was the 98th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →17 of the 145 studies testing carboplatin in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
RenJi Hospital · Sites in China
Ages 18–70 · Women only
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Women only
University of Kansas Medical Center · Sites in United States
Ages 18+
Jazz Pharmaceuticals · Sites in United States, Germany, Italy and 1 more country
Ages 18+
By country, each count listing its studies:
Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
145 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 109 · Phase 3 19 · Phase 4 5
First in 1991; this study’s year is marked. 11 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 110 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 60 across the 142 interventional studies. Of the 92 that completed or were terminated, 49 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 145 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 98th largest by enrollment of the 170 interventional ones that give a count, is one of 20 that started in 2015, is one of 11 in phase 4, and was the 142nd registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
9 of the studies testing carboplatin in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02455141Phase 3Shanghai Jiao Tong University School of MedicineAdjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer | 2027-03 |
| NCT07283692RenJi HospitalNeoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) | 2026-12 |
| NCT05645380University of Kansas Medical CenterNeoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | 2026-12 |
| NCT04771871University College Hospital, IbadanMicroRNA Profiles in Triple Negative Breast Cancer | 2027-03 |
| NCT06407310Tel Aviv Medical CenterNeoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer | 2027-04-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 145 studies testing carboplatin in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a prospective, Phase IV, multi-center, single arm, open-label, interventional study to evaluate the safety of trastuzumab for the treatment of human epidermal growth factor receptor 2 protein (HER2)-positive node positive or high risk node negative breast cancer participants with regimen consisting of doxorubicin and cyclophosphamide followed by either paclitaxel or docetaxel (AC-TH Regimen) or a regimen consisting of docetaxel and carboplatin (TCH Regimen) in Indian population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive trastuzumab as a part of either AC-TH or TCH treatment regimen. The choice of the regimen will be based on investigator's discretion referring the local prescribing document of trastuzumab. AC-TH consists of doxorubicin and cyclophosphamide followed by either paclitaxel or docetaxel. TCH consists of docetaxel and carboplatin. Trastuzumab will be common in both treatment regimens and could be administered weekly or every 3 weeks, as per investigator discretion. Each cycle will be of 3 weeks.
Drug: Carboplatin · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Paclitaxel · Drug: Trastuzumab
TCH regimen: Carboplatin dose = Target Area Under Curve (AUC) (6 milligrams\*milliliter/minute \[mg\*mL/min\]) multiplied by (Glomerular Filtration Rate \[GFR\] + 25). Carboplatin will be administered as IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
AC-TH regimen: Cyclophosphamide 600 mg/m\^2 IV bolus every 3 weeks for 4 cycles (Cycles 1 to 4).
AC-TH regimen: Docetaxel 100 mg/m\^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8). TCH regimen: Docetaxel 75 mg/m\^2 IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
Participants will receive Doxorubicin 60 mg/m\^2 administered as I.V. bolus injection over 5 to 15 minute every 3 weeks for 4 cycles for AC-TH regimen.
AC-TH regimen: Paclitaxel 175 mg/m\^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8).
AC-TH regimen: For weekly administration, 4 milligrams per kilograms (mg/kg) loading dose on Day 1 of Cycle 5, followed by 2 mg/kg on Day 8 of Cycle 5 and 2 mg/kg every week for 4 cycles (up to Cycle 8). For 3 weekly administration, 8 mg/kg loading dose on Day 1 of Cycle 5, followed by 6 mg/kg every 3 for 4 cycles (up to Cycle 8). From Day 1 of Cycle 9, 6 mg/kg will be administered every 3 weeks up to Cycle 22. TCH regimen: For weekly administration, 4 mg/kg loading dose followed by 2 mg/kg weekly from Cycles 1 to Cycle 6. For 3 weekly administration, 8 mg/kg loading dose followed 6 mg/kg every 3 weeks from Cycles 1 to 6. From Cycle 7, 6 mg/kg every 3 weeks up to Cycle 18. All administrations will be intravenous (IV) infusion.
Clinically Significant Changes in Cardiac Function As Determined by Left Ventricular Ejection Fraction (LVEF) Measurements Using Echocardiography
LVEF assessments were performed every three months (four cycles) using echocardiogram
Time frame: Baseline to every 4 cycles up to Cycle 21 (AC-TH), every 4 cycles up to Cycle 17 (TCH) (each cycle is 21 days), at study treatment completion (12 months post baseline) at 6 month (18 months post baseline) and 12 month follow-up (24 months post baseline)
Percentage of Participants With Adverse Events
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with the treatment. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events.
Time frame: Baseline up to approximately 5 years and 10 months
Disease Free Survival (DFS)
DFS was defined as time from the date of first study treatment to the date of local, regional or distant recurrence, contra-lateral breast cancer or death due to any cause. Local, regional or distant recurrence, and contra-lateral breast cancer was assessed by combination of physical examination, mammography and pelvic examination.
Time frame: The date of first study treatment to the date of local, regional or distant recurrence, contra-lateral breast cancer or death due to any cause within 12 months from the last dose of Trastuzumab for every participant
Overall Survival (OS)
Overall survival was defined as time from the date of first study treatment until date of death, regardless of the cause of death.
Time frame: Time from the date of first study treatment until date of death, regardless of the cause of death within 12 months from the last dose of Trastuzumab for every participant. The follow up period was 52 weeks from the last dose of treatment in both arms.
The study was conducted at 6 investigational sites in India.
| Milestone | Trastuzumab With AC-TH Regimen | Trastuzumab With TCH Regimen |
|---|---|---|
| Started | 58 | 52 |
| Completed | 53 | 50 |
| Not completed | 5 | 2 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Disease progression | 0 | 1 |
| Withdrew: Withdrew consent | 2 | 1 |
| Withdrew: Any other reason which the investigator deemed participant unsuitable for enrollment into the study | 1 | 0 |
LVEF assessments were performed every three months (four cycles) using echocardiogram
| Percentage of LVEF | Trastuzumab With AC-TH Regimen | Trastuzumab With TCH Regimen |
|---|---|---|
| Baseline | 60.1 ± 6.17 | 62.1 ± 2.30 |
| Cycle 5 | -0.2 ± 4.71 | -0.4 ± 2.72 |
| Cycle 9 | -0.5 ± 4.64 | -1.0 ± 2.98 |
| Cycle 13 | -2.0 ± 6.94 | -1.0 ± 2.36 |
| Cycle 17 | -1.8 ± 4.77 | -1.1 ± 3.15 |
| Cycle 21 | -1.8 ± 4.88 | — |
| Study Completion Visit | -3.3 ± 6.59 | -0.7 ± 2.72 |
| 6 Month Follow Up | -1.6 ± 5.89 | -0.3 ± 3.18 |
| 12 Month Follow Up | -2.2 ± 6.28 | -0.4 ± 2.92 |
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with the treatment. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events.
| Participants | Trastuzumab With AC-TH Regimen | Trastuzumab With TCH Regimen |
|---|---|---|
| Percentage of Participants With Adverse Events | 46 | 51 |
DFS was defined as time from the date of first study treatment to the date of local, regional or distant recurrence, contra-lateral breast cancer or death due to any cause. Local, regional or distant recurrence, and contra-lateral breast cancer was assessed by combination of physical examination, mammography and pelvic examination.
| Months | Trastuzumab With AC-TH Regimen | Trastuzumab With TCH Regimen |
|---|---|---|
| Disease Free Survival (DFS) | NA (NA to NA) | NA (NA to NA) |
Overall survival was defined as time from the date of first study treatment until date of death, regardless of the cause of death.
| Months | Trastuzumab With AC-TH Regimen | Trastuzumab With TCH Regimen |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
Collected over Baseline up to approximately 5 years and 10 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trastuzumab With AC-TH Regimen | 1/56 (1.8%) | 11/56 (19.6%) | 46/56 (82.1%) |
| Trastuzumab With TCH Regimen | 1/52 (1.9%) | 9/52 (17.3%) | 51/52 (98.1%) |
| Event | Trastuzumab With AC-TH Regimen | Trastuzumab With TCH Regimen |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/56 | 2/52 |
| Disease progressionGeneral disorders | 0/56 | 2/52 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/56 | 0/52 |
| NeutropeniaBlood and lymphatic system disorders | 2/56 | 1/52 |
| PyrexiaGeneral disorders | 2/56 | 1/52 |
| AnaemiaBlood and lymphatic system disorders | 0/56 | 1/52 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/56 | 1/52 |
| VomitingGastrointestinal disorders | 0/56 | 1/52 |
| FatigueGeneral disorders | 0/56 | 1/52 |
| Viral infectionInfections and infestations | 0/56 | 1/52 |
| Event | Trastuzumab With AC-TH Regimen | Trastuzumab With TCH Regimen |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 12/56 | 27/52 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/56 | 22/52 |
| LeukopeniaBlood and lymphatic system disorders | 22/56 | 3/52 |
| Urinary tract infectionInfections and infestations | 14/56 | 3/52 |
| AstheniaGeneral disorders | 0/56 | 12/52 |
| PyrexiaGeneral disorders | 12/56 | 11/52 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/56 | 10/52 |
| DiarrhoeaGastrointestinal disorders | 3/56 | 9/52 |
| VomitingGastrointestinal disorders | 0/56 | 9/52 |
| FatigueGeneral disorders | 3/56 | 8/52 |
Intent-to-treat (ITT) population included all participants enrolled in the study.
| Age, Continuous(Years) | Trastuzumab With AC-TH Regimen | Trastuzumab With TCH Regimen | Total |
|---|---|---|---|
| Mean | 51.95 ± 7.96 | 51.19 ± 10.94 | 51.59 ± 9.45 |
| Sex: Female, Male(Participants) | Trastuzumab With AC-TH Regimen | Trastuzumab With TCH Regimen | Total |
|---|---|---|---|
| Female | 58 | 52 | 110 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Trastuzumab With AC-TH Regimen | Trastuzumab With TCH Regimen | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 58 | 52 | 110 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2015 to primary completion in Jun 2021, 70 months.
Results were first posted in Oct 2022, 1 year 3 months after primary completion.
Of 130 phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's 70 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carboplatin · Cyclophosphamide · Docetaxel · Doxorubicin · Paclitaxel · Trastuzumab